CHEK1 and gastric cancer: In the context of gastric cancer, several studies have emphasized the crucial role of DDR pathways in the pathogenesis and progression of gastric cancer, highlighting several molecular markers with diagnostic, prognostic, and therapeutic relevance as recently reviewed by Wang M. and Xie C. [60] Here, we aimed to review clinical and emerging pre-clinical evidence on the role of ATR-CHK1 axis inhibitors in gastric cancer therapy.